Verastem Correlations
VSTM Stock | USD 6.03 0.21 3.61% |
The current 90-days correlation between Verastem and Viking Therapeutics is 0.28 (i.e., Modest diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verastem moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verastem moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Verastem Correlation With Market
Good diversification
The correlation between Verastem and DJI is -0.08 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Verastem and DJI in the same portfolio, assuming nothing else is changed.
Verastem |
Moving against Verastem Stock
0.33 | MDGL | Madrigal Pharmaceuticals | PairCorr |
0.31 | KRYS | Krystal Biotech | PairCorr |
0.65 | SGMO | Sangamo Therapeutics | PairCorr |
0.4 | AMLX | Amylyx Pharmaceuticals | PairCorr |
0.38 | STOK | Stoke Therapeutics | PairCorr |
0.34 | AFMD | Affimed NV | PairCorr |
0.34 | AGIO | Agios Pharm | PairCorr |
0.34 | CRVS | Corvus Pharmaceuticals | PairCorr |
0.31 | TERN | Terns Pharmaceuticals Downward Rally | PairCorr |
0.31 | DAWN | Day One Biopharmaceu | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Verastem Stock performing well and Verastem Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Verastem's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
VKTX | 3.42 | (0.84) | 0.00 | (0.83) | 0.00 | 4.89 | 39.28 | |||
TRVN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
KPTI | 3.49 | (0.51) | 0.00 | 0.80 | 0.00 | 8.97 | 26.35 | |||
ACRX | 4.72 | 0.61 | 0.10 | (0.66) | 4.26 | 13.85 | 29.52 | |||
INFI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Verastem Corporate Management
Jonathan Pachter | Chief Officer | Profile | |
Michael Crowther | Chief Officer | Profile | |
Sean Flynn | Gen VP | Profile | |
MD MSc | Head Strategy | Profile | |
Robert Weinberg | CoFounder Board | Profile | |
Daniel Calkins | Interim Officer | Profile |